DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q96nrh/ventilator) has announced the addition of the "Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ventilator Associated Pneumonia (VAP) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Adenium Biotech ApS
- Aridis Pharmaceuticals LLC
- AstraZeneca Plc
- Cardeas Pharma Corp.
- Dong-A Socio Group
- MedImmune, LLC
- Meiji Seika Pharma Co., Ltd.
- Merck & Co., Inc.
- Nabriva Therapeutics AG
- Savara Inc.
- Serendex Pharmaceuticals A/S
- Tetraphase Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/q96nrh/ventilator